AtaiBeckley (NASDAQ:ATAI) saw its common stock added to the NASDAQ Biotechnology Index (NBI) prior to the market open on Dec. 22, 2025, marking a significant milestone in the company’s evolution as a leader in neuropsychiatric drug development.
The inclusion, part of Nasdaq’s annual December re-ranking, follows a highly active year that saw the company consolidate its market position through aggressive fundraising and strategic M&A.
The company’s ascension to the index comes on the heels of a successful 2025 campaign in which it raised approximately $300 million in capital.
This financial runway has been utilized to push multiple clinical programs into late-stage development, specifically focusing on psychedelic-based therapies for depression and anxiety.
A core driver of this momentum was the strategic combination between atai Life Sciences and Beckley Psytech, a deal that streamlined the sector's pipeline and created a more formidable competitor in the burgeoning mental health space.
Beyond clinical progress, AtaiBeckley is in the final stages of a U.S. corporate domiciliation, expected to be completed by year-end.
This move is designed to simplify its corporate structure and potentially broaden its appeal to a wider base of American institutional investors.
The NASDAQ Biotechnology Index is a widely followed benchmark that tracks securities meeting stringent market-capitalization, liquidity, and "seasoning" requirements.